ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $252 | -10.0% | 2,002 | -33.2% | 0.02% | -28.6% |
| Q3 2023 | $280 | -99.9% | 2,995 | +69.1% | 0.03% | +86.7% |
| Q1 2022 | $208,000 | -56.6% | 1,771 | -50.2% | 0.02% | -69.4% |
| Q4 2021 | $479,000 | +116.7% | 3,558 | +111.5% | 0.05% | +133.3% |
| Q2 2021 | $221,000 | -19.9% | 1,682 | -5.9% | 0.02% | -55.3% |
| Q3 2020 | $276,000 | -56.3% | 1,787 | -67.4% | 0.05% | +27.0% |
| Q2 2019 | $631,000 | +173.2% | 5,483 | +179.2% | 0.04% | +184.6% |
| Q1 2019 | $231,000 | +1.8% | 1,964 | -43.5% | 0.01% | +8.3% |
| Q1 2018 | $227,000 | – | 3,478 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |